MECP2 and Alzheimer disease: The expression of Nlgn1 showed similar alterations upon MECP2 overexpression and LPS/IFNγ treatment to Bdnf. A recent study suggested that Aβ oligomers can reduce the levels of NLGN1 and that NLGN1 levels were decreased in the hippocampus of AD patients [72].